Phase I Study to Evaluate the Safety of Dexibuprofen 200mg Under Fasting and Fed Conditions
Phase I Clinical Study, Open-label, Randomized, Parallel to Evaluate the Safety of the 200 mg Dexibuprofen Following Single and Multiple Dose Oral Administration in Healthy Participants of Both Sexes Under Fasting and Fed Conditions.
Sponsor: Apsen Farmaceutica S.A.
A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by Apsen Farmaceutica S.A. and has accumulated 8 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Jan 2021 — Mar 2023 [monthly]
Unknown Status PHASE1
-
Jan 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Not Yet Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2020 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Apsen Farmaceutica S.A.
For direct contact, visit the study record on ClinicalTrials.gov .